2017 CMHC Accreditation Information – San Diego

Title:

CMHC Regional Conference Series: Focus on Frontline Education

Date

San Diego | May 6, 2017

Target Audience

The CMHC is designed for the primary care audience responsible for the prevention, diagnosis, and management of cardiometabolic risk including primary care clinicians (PCPs), endocrinologists, diabetologists, pharmacists, nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals.

Statement of Need/Program Overview

The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease already affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden can be expected to increase.

This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The CMHC presents an especially valuable venue for this educational outreach with sessions fostering a collaborative, multidisciplinary approach to care.

This regional series will translate the latest cutting edge medical research into practical, clinical strategies for preventing, delaying, and managing cardiovascular and metabolic disorders. The goal is to provide the primary care audience with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
  • Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
  • Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.
  • Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.
  • Apply a personalized medicine approach to incorporate biomarkers, imaging and therapies into individualized patient treatment plans.

Faculty

San Diego faculty listing: Click here

Program Agenda

San Diego: Click here

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 5.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacotherapy hours will be available for this activity. This activity has been approved for 0.4 pharmacotherapy hours.

Pharmacist Accreditation Statement

ACPEGlobal Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 5.25 contact hour(s) (0.525 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-17-124-L01-P)
This is a knowledge based activity.

Dietician Accreditation Statement

CPE

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 5.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.
CPE Provider #GE012

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the CMHC Program Evaluation. A link to the online evaluation will be emailed to all participants within 2-3 business days. Online evaluations must be completed by within 2 weeks of the meeting. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form.

Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before July 1, 2017.

Fee Information & Refund/Cancellation Policy

There is a registration fee for this educational activity, registration information can be found here.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Christie M. Ballantyne, MD

Grant/Research Support (all significant, all paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, ADA
Consultant/Independent Contractor: Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

George L. Bakris, MD

Consultant/Independent Contractor: Janssen, Relypsa, AbbVie, Merck, Boehringer-Ingelheim, Sanofi, Pfizer

Lawrence Blonde, MD

TBD

David A. Calhoun, MD

Consultant/Independent Contractor: Valencia Technologies
Grant/Research Support: Medtronic, ReCOR

Robert H. Eckel, MD

Consultant/Independent Contractor: Sanofi/Regeneron-Expert Witness

David A. Ehrmann, MD

TBD

Keith C. Ferdinand, MD

Consultant/Independent Contractor: Quantum Genomics, Novartis, Amgen, Sanofi, Eli Lilly
Grant/Research Support: Boehringer Ingelheim

Barry H. Greenberg, MD

Consultant/Independent Contractor: Novartis
Speaker’s Bureau: Novartis, Otsuka

Philip B. Gorelick, MD

Consultant/Independent Contractor: Janssen, Johnson and Johnson, New Haven Pharmaceuticals, Medtronic
Other/Royalty: Steering Committee for Bayer ARRIVE TrailX

Thomas W. Heinrich, MD

Dr. Heinrich has nothing to disclose.

Samuel Klein, MD

Consultant/Independent Contractor: Dannon/Yakult; Novo Nordisk; Aspire Bariatrics; Endobar; Pfizer; Janssen; REMD Biotherapeutics; Merck
Stock Shareholder: Aspire Bariatrics, Human Longevity Inc.

James S. Manning, MD

Speakers’ Bureau/Consultant: Sunovion, Otsuka, Takeda/Lundbeck

Pamela B. Morris, MD

Consultant/Independent Contractor: Amgen, Sanofi-Regeneron, AstraZeneca

Sunder Mudaliar, MD

Consultant/Independent Contractor: AstraZeneca
Grant/Research Support: To the Veterans Medical Research Foundation and the University from: NIH/Janssen/Astra-Zeneca/Lexicon
Honoraria: AstraZeneca
Speaker’s Bureau: AstraZeneca

Elizabeth Ofili, MD

Consultant/Independent Contractor: Bristol-Myers Squibb, Novartis, Janssen Research and Development, Arbor Pharmaceuticals and Merck & Co.
Grant/Research Support: National Institute of Health

Anne L. Peters, MD

Consultant/Independent Contractor: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Lexicon, Medscape, Merck, Novo Nordisk, Omada Health, OptumRx, Perrigo, Roche, sanofi
Grant/Research Support: Dexcom
Speaker’s Bureau: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Janssen
Other/Royalty: Editorial Fee: Medscape

Donna H. Ryan, MD

Consultant/Independent Contractor: Novo Nordisk, Merck, Orexigen, Janssen, CVK, AstraZeneca
Speaker’s Bureau: Novo Nordisk, Eisai, Orexigen, KwangDong
Stock Shareholder: Gila Therapeutics, Scientific Intake

Jay S. Skyler, MD

Consultant/Independent Contractor: Adocia, AstraZeneca, BD, Boehringer Ingelheim/Eli Lilly Collaboration, Dance Biopharm, DiaVacs, Elcelyx Therapeutics, Genentech, Immnomolecular Therapeutics, Intarcia Therapeutics, Intrexon, Merck, Orgenesis, Sanofi Diabetes, Servier, vTv Therapeutics (Trans Tech), Valeritas
Grant/Research Support: Mesoblast, Viacyte
Ownership Interest/Shareholder: Dance Biopharm, DexCom, Inc., Elizabeth Therapeutics, Ideal Life, Intrexon, Moerae Matrix, Orgenesis, Paean Therapeutics, SynAlpha Therapeutics, VasoPrep Surgical
Board of Directors Member: DexCom, Inc., Elizabeth Therapeutics, Moerae Matrix, Paean Therapeutics, SynAlpha, VasoPrep Surgical.
Scientific Advisory Board Member: Adocia, Intarcia Therapeutics, Intrexon, Sanofi Diabetes, Viacyte
Other/Royalty: Dexcom Inc., Intarcia Therapeutics, Sanofi Diabetes

Karol E. Watson, MD

Consultant: Amarin, Boehringer Ingelheim, Quest
Honoraria: Amarin, Boehringer Ingelheim, Quest
Speaker’s Bureau: Boehringer Ingelheim


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager

Reported Financial Relationship

Ashley Marostica, RN, MSN

Nothing to disclose

Lindsay Borvansky

Nothing to disclose

Andrea Funk

Nothing to disclose

Laura Gilsdorf

Nothing to disclose

Erin Franceschini, MS

Nothing to disclose

Amanda Jamrogiewicz

Nothing to disclose

Karin McAdams

Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Educational Grant Support

The 2017 CMHC Regional Conference Series is supported in part by an independent and unrestricted educational grant from Arbor Pharmaceuticals, LLC. Please continue to check this page for updates. For satellite symposium educational support, please click here.

Joint Providership Statement

UMA Global

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

CMHC